Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive topline results from the clinical study OX640-002. The study evaluated the performance in subjects with and without allergic ...
GLP-1 drugs, widely used for treating metabolic disorders, often face issues with long term tolerability, leading to side effects such as sarcopenia and bone density loss. These complications ...